Plexus Corp.

Plexus Corp. (PLXS) Market Cap

Plexus Corp. has a market capitalization of $6.39B.

Financials based on reported quarter end 2026-01-03

Price: $238.58

0.65 (0.27%)

Market Cap: 6.39B

NASDAQ · time unavailable

CEO: Todd Kelsey

Sector: Technology

Industry: Hardware, Equipment & Parts

IPO Date: 1986-02-05

Website: https://www.plexus.com

Plexus Corp. (PLXS) - Company Information

Market Cap: 6.39B · Sector: Technology

Plexus Corp., together with its subsidiaries, provides electronic manufacturing services in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. It offers design and development, supply chain, new product introduction, and manufacturing solutions, as well as aftermarket services to companies in the healthcare/life sciences, industrial/commercial, aerospace/defense, and communications market sectors. Plexus Corp. was founded in 1979 and is headquartered in Neenah, Wisconsin.

Analyst Sentiment

59%
Buy

Based on 18 ratings

Analyst 1Y Forecast: $177.86

Average target (based on 3 sources)

Consensus Price Target

Low

$195

Median

$223

High

$250

Average

$223

Downside: -6.7%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PLEXUS CORP (PLXS) — Investment Overview

🧩 Business Model Overview

Plexus Corp (PLXS) is a leading provider of electronic manufacturing services (EMS), focusing on complex product design, manufacturing, and aftermarket services for original equipment manufacturers (OEMs) globally. Its business is anchored in an engineering-centric, customer-intimate approach that enables it to serve clients with highly complex, regulated products, often requiring strict quality, reliability, and regulatory standards. Plexus positions itself as an essential partner in the full product lifecycle, offering engineering, new product introduction (NPI), prototyping, manufacturing, and after-market support. The company differentiates from lower-margin, commoditized EMS competitors by targeting high-mix, low-to-medium volume segments where engineering collaboration and flexibility are critical.

💰 Revenue Streams & Monetisation Model

Plexus Corp’s revenue is primarily generated through long-term manufacturing agreements with OEMs in sectors such as Healthcare/Life Sciences, Industrial/Commercial, Aerospace/Defense, and Communications. The majority of revenue is derived from assembly and testing of custom electronics and electro-mechanical products. Additional revenue streams include engineering design services, prototyping, supply chain management, and post-manufacturing services (such as repair and refurbishment). The company operates a contract manufacturing business model, with pricing typically structured as cost-plus or fixed price, providing revenue visibility and recurring business from established customer relationships. Plexus benefits from customer stickiness, driven by high switching costs and the integration of its teams into customers’ product development and supply chain processes.

🧠 Competitive Advantages & Market Positioning

Plexus stands out in the EMS industry due to its specialized focus on high-reliability and highly regulated end-markets. Its deep technical and engineering capabilities allow it to serve industries with demanding standards, such as healthcare and aerospace. Unlike large-scale contract manufacturers focused on commoditized consumer electronics, Plexus targets high-value opportunities with stringent compliance, reliability, and quality requirements—leading to defensible market positions and margin stability. Long-standing customer relationships, intellectual property co-development, and regulatory know-how further strengthen the company’s competitive moat. Its global footprint—with operations in the Americas, EMEA, and Asia Pacific—enables agile supply chain solutions and risk mitigation for clients facing dynamic geopolitical landscapes or supply chain disruptions.

🚀 Multi-Year Growth Drivers

Several secular and company-specific trends support long-term growth: - **Increasing Outsourcing in Complex Segments:** OEMs are accelerating outsourcing of electronics manufacturing, especially for sophisticated products with complex regulatory requirements. - **Healthcare and Life Sciences Expansion:** Growth in medical device innovation and the need for complex, compliant manufacturing are expanding addressable markets. - **Industrial and Automation Investments:** Ongoing digitalization and automation in industrial markets drives new product introductions and higher EMS demand. - **Supply Chain Diversification:** Global customers seek partners with distributed manufacturing capacity and robust compliance, favoring providers like Plexus. - **Engineering Services Upsell:** Engineering-led partnerships often lead to deeper integration and expanded wallet share through aftermarket services and design upgrades.

⚠ Risk Factors to Monitor

Investors should be mindful of several risks inherent to the Plexus Corp investment case: - **Customer Concentration:** A material portion of revenue is often tied to a small group of large customers, increasing exposure to contract renegotiations or demand swings. - **End-Market Volatility:** Demand in sectors like healthcare or aerospace can be subject to regulatory, economic, or technological disruptions. - **Supply Chain Complexity:** Plexus’s global supply chain exposes it to risks from component shortages, tariffs, or logistical bottlenecks. - **Execution on Complex Programs:** Managing complex, high-mix production requires ongoing investment in talent and processes. Execution failures can result in margin compression or reputational harm. - **Competitive Pressure:** Larger EMS providers may expand upmarket, increasing competition for high-reliability manufacturing programs.

📊 Valuation & Market View

In the context of the EMS sector, Plexus Corp is typically valued at a premium to mass-market, low-margin peers, reflecting its focus on higher-value, regulated markets and stable customer relationships. Valuation metrics such as enterprise value to EBITDA or price-to-earnings multiples often recognize its mid-to-high single-digit operating margins, consistent free cash flow, and growth in high-reliability segments. The company’s capital-light strategy and disciplined working capital management support healthy balance sheets and potential for shareholder returns. Relative to competitors, Plexus’s defensible niche and recurring revenue base underpin analyst expectations for above-sector-average margin durability and organic growth. Nonetheless, valuation is sensitive to customer order pipelines, program wins/losses, and sector supply chain dynamics.

🔍 Investment Takeaway

Plexus Corp represents a differentiated EMS investment, leveraging technical depth, regulatory expertise, and global operations to serve demanding and growing end-markets. Its business model is underpinned by durable customer relationships, value-added engineering, and exposure to secular growth in outsourced manufacturing, particularly in healthcare, industrial automation, and aerospace. The company’s balanced risk profile and strong cash generation support a compelling long-term thesis, with risks primarily centered around customer concentration and end-market volatility. For investors seeking exposure to complex electronics manufacturing, integrated services, and above-average industry margins, Plexus offers an attractive opportunity within the industrial technology and EMS landscape.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-01-03

"PLXS’ latest quarter (ended 2026-01-03) reported Revenue of $1.07B and Net Income of $41.2M (EPS $1.54). On a QoQ basis, Revenue rose ~1.1%, but Net Income fell ~19.9% (EPS down ~19.4%). YoY (vs. 2024-12-28, closest available “same-quarter” proxy), Revenue grew ~9.6% while Net Income increased ~10.5% (EPS up ~11.6%). Profitability weakened sequentially: net margin contracted from ~4.86% (2025-09-27) to ~3.85% (2026-01-03), indicating higher costs or less favorable mix despite modest top-line growth. Balance sheet resilience remains solid: total assets increased to ~$3.19B QoQ (+~1.6%) and equity rose to ~$1.48B (+~1.8%). Net debt remains negative (net cash), but liquidity cushion tightened vs. the prior quarter (net cash decreased from about -$131M to -$29M). Shareholder returns look strong: the stock is up ~87.5% over the last 1Y, with no dividend support (dividend yield 0%). Buybacks aren’t provided, so total shareholder return is largely price-driven. Valuation appears more demanding than a year ago (P/E ~24.7 vs ~28.7 in 2024-12-28 and ~18.7 in 2025-09-27), and the consensus target (~$222.5) is slightly below the current price (~$228.6)."

Revenue Growth

Positive

Revenue increased ~1.1% QoQ (from ~$1.06B to ~$1.07B) and ~9.6% YoY (from ~$0.98B to ~$1.07B). Growth remains positive but is slower sequentially.

Profitability

Fair

Net Income declined ~19.9% QoQ (EPS down ~19.4%), with net margin contracting from ~4.86% to ~3.85%. YoY profitability improved (~+10.5% Net Income), but sequential trend is weaker.

Cash Flow Quality

Neutral

Net Income is positive and grew YoY (~+10.5%), but the lack of cash flow statement detail limits confidence in cash conversion. No dividends and buybacks aren’t provided.

Leverage & Balance Sheet

Positive

Equity strengthened QoQ (~+1.8%) and assets rose (~+1.6%). Net debt is still negative (net cash), though net cash decreased vs. the prior quarter (from ~-$131M to ~-$29M).

Shareholder Returns

Strong

Total return is strongly supported by price momentum: ~+87.5% over 1Y. Dividend yield is 0% and buybacks aren’t specified, so returns appear primarily capital-appreciation-driven.

Analyst Sentiment & Valuation

Neutral

Consensus target (~$222.5) is slightly below current price (~$228.6), implying modest upside. P/E has risen vs the prior quarter (~18.7 to ~24.7), suggesting valuation pressure.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Plexus delivered solid Q1 results with 10% y/y revenue growth, EPS at the high end, and strong program wins—especially a record quarter in Aerospace & Defense. Management raised confidence to meet or exceed the high end of its 9%–12% FY26 revenue target and is targeting a 6% non-GAAP operating margin as volumes ramp. While seasonal costs, higher incentive compensation, and working capital investment pose near-term headwinds, demand momentum, robust funnels, and operational efficiency underpin a positive outlook with ~$100M FY26 free cash flow.

Growth

  • Revenue $1.07B, up ~10% y/y; fourth consecutive quarter of sequential growth
  • Q2 revenue guidance $1.11B–$1.15B (+6% q/q, +15% y/y at midpoint)
  • FY26 revenue expected to meet or exceed high end of 9%–12% target
  • Aerospace & Defense and Healthcare/Life Sciences expected to grow above 9%–12% in FY26; Industrial to approach target with strong semicap

Business Development

  • 22 new manufacturing program wins valued at ~$283M annualized when fully ramped
  • Record quarterly A&D wins of ~$220M, including space, security detection (production + services), and unmanned systems
  • Healthcare wins ~$40M: next-gen imaging in Haining, China; cabinet subassemblies in Oradea, Romania expanding regional support
  • Industrial wins ~$23M: semicap next-gen launch volumes (Neenah, WI); robotic material handling solution (Oradea, RO)
  • Qualified manufacturing funnel remains robust at ~$3.6B; A&D engineering solutions funnel at record high

Financials

  • Non-GAAP EPS $1.78, at high end of guidance
  • Gross margin 9.9%; SG&A $51.7M; non-GAAP operating margin 5.8%
  • Non-operating expense $3.4M (lower interest and FX losses than expected)
  • Cash from operations used ~$16M; capex ~$35M (Malaysia facility carryover); net cash outflow ~$51M
  • Repurchased ~153k shares for $22.4M; ~$63M remaining on authorization
  • ROIC 13.2% (~420 bps above WACC)
  • Cash cycle 69 days (up 6 days q/q on inventory to support ramps)

Capital & Funding

  • Ended quarter in net cash position; $60M drawn on revolver with $440M available
  • FY26 free cash flow guidance reaffirmed at ~+$100M despite 1H working capital usage
  • FY26 capex raised to $100M–$120M to support growth
  • All excess cash intended for shareholder value creation (including buybacks)

Operations & Strategy

  • Ongoing investments in capacity, technology, facilities (new Malaysia site) and advanced capabilities
  • Focus on achieving 6% non-GAAP operating margin via efficiency and leverage
  • Engineering Solutions funnel third largest in company history
  • ESG: 100% renewable electricity for Penang campus via TNB green tariff; multiple HR Asia awards recognizing workplace and sustainability

Market & Outlook

  • Q2 guidance: non-GAAP operating margin 5.6%–6.0%; EPS $1.80–$1.95; gross margin 9.9%–10.2%; SG&A $54M–$55M; tax rate 16%–18%; diluted shares ~27.2M
  • Demand strength in Healthcare (surgical/monitoring), semicap, industrial equipment, and multiple A&D subsectors
  • A&D Q2 expected up mid-single digits q/q on demand improvement and new ramps
  • Healthcare Q2 flat to up low single digits q/q; Industrial Q2 up high single to low double digits q/q
  • Cash cycle expected 65–69 days in Q2; breakeven to slight cash usage in Q2

Risks Or Headwinds

  • Seasonal compensation increases and U.S. payroll tax reset in Q2
  • Higher variable incentive compensation tied to strong performance
  • Increased working capital needs and higher inventory to support program ramps
  • Rising interest expense as capitalization of interest on site additions subsides
  • FX losses and end-of-year customer inventory management impacted A&D in Q1
  • Softness persists in certain Industrial subsectors outside semicap and equipment

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PLXS Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PLXS)

© 2026 Stock Market Info — Plexus Corp. (PLXS) Financial Profile